Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Carlyle Pays $260 Million for 5% Stake in Shenzhen Salubris Pharma

publication date: Sep 1, 2020

Carlyle Group, a US private equity firm, invested $260 million in Shenzhen Salubris Pharma to buy a 5% stake. Salubris makes finished drugs and medical devices for cardiovascular, oncology and anti-infective needs. In a statement, Carlyle said China's new methods of reimbursement will cause consolidation among domestic generic drug companies, giving the surviving companies greater market share. With Carlyle's help, Salubris will expand into the US, possibly through M&A. More details....

Stock Symbol: (SHZ: 002264)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.